智通财经APP获悉，里昂发布研报称，相信中国生物制药(01177)已进入长期上升周期，主要受惠于2025至2027年持续推出创新药物;研发能力提升;及中国对创新药物的政策更为有利。因此，该行修订对中生制药于2025至2027年纯利预测，分别升1%、降3%及升25%，并将目标价由7港元上调至9.2港元，重申“跑嬴大市”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.